Trial · NCT04092452
Results by group1,077
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,077
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)]. | Placebo | 33.3 | 90% Confidence Interval 22.2 to 45.5 | Percentage of participants | |
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)]. | PF-06650833 400mg QD | 34.0 | 90% Confidence Interval 22.7 to 46.5 | Percentage of participants | |
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)]. | PF-06700841 45mg QD | 51.9 | 90% Confidence Interval 39.7 to 64.0 | Percentage of participants | |
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation (NRI)]. | PF-06826647 400mg QD | 37.0 | 90% Confidence Interval 25.5 to 50.0 | Percentage of participants | |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | Placebo | Week 1 | 16.7 | 90% Confidence Interval 8.6 to 27.7 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06650833 400mg QD | Week 1 | 12.8 | 90% Confidence Interval 5.7 to 22.7 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06700841 45mg QD | Week 1 | 15.4 | 90% Confidence Interval 7.9 to 25.4 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06826647 400mg QD | Week 1 | 21.3 | 90% Confidence Interval 12.0 to 32.2 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | Placebo | Week 2 | 25.0 | 90% Confidence Interval 15.1 to 36.9 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06650833 400mg QD | Week 2 | 31.9 | 90% Confidence Interval 20.8 to 44.4 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06700841 45mg QD | Week 2 | 32.0 | 90% Confidence Interval 21.2 to 43.4 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06826647 400mg QD | Week 2 | 28.3 | 90% Confidence Interval 17.6 to 40.4 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | Placebo | Week 4 | 31.9 | 90% Confidence Interval 20.8 to 44.4 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06650833 400mg QD | Week 4 | 40.4 | 90% Confidence Interval 28.3 to 53.5 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06700841 45mg QD | Week 4 | 39.2 | 90% Confidence Interval 27.7 to 51.6 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06826647 400mg QD | Week 4 | 27.7 | 90% Confidence Interval 17.2 to 40.3 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | Placebo | Week 6 | 37.5 | 90% Confidence Interval 26.4 to 50.0 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06650833 400mg QD | Week 6 | 38.3 | 90% Confidence Interval 27.1 to 51.3 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06700841 45mg QD | Week 6 | 44.2 | 90% Confidence Interval 32.4 to 56.3 | Percentage of participants |
| Percentage of Participants Achieving HiSCR Response at Weeks 1, 2, 4, 6, 8, and 12 - MR (FAS, NRI). | PF-06826647 400mg QD | Week 6 | 41.3 | 90% Confidence Interval 29.0 to 54.5 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04092452/results